Compare PASG & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | BFRI |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 16.3M |
| IPO Year | 2020 | 2021 |
| Metric | PASG | BFRI |
|---|---|---|
| Price | $4.65 | $1.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $14.00 | $2.75 |
| AVG Volume (30 Days) | 11.3K | ★ 563.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $3.29 | $0.57 |
| 52 Week High | $20.00 | $1.61 |
| Indicator | PASG | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 64.67 |
| Support Level | $4.27 | $0.78 |
| Resistance Level | $4.95 | N/A |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 52.24 | 68.33 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.